Minimal residual disease monitoring in paztients with multiple myeloma that they have obtain a good response to the maintenance treatment with revlimid

Phase 1

Active, not recruiting

• Conditions: Patients with Multiple Myeloma in maintenance treatment with Lenalidomide; MedDRA version: 14.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2012-004063-52-IT
• Lead Sponsor: FONDAZIONE NEOPLASIE SANGUE ONLUS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-11
• Last Update Posted: 14 March 2022

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

- Patient has achieved at least a Very Good Partial Response before starting maintenance treatment
- Availability of a bone marrow sample at diagnosed stored in the institution tissue bank to create patient-specific probes derived from IgH rearrangement
Are the trial subjects under 18? yes
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

ll

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified